MBRX - Moleculin Biotech, Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD

Moleculin Biotech, Inc.

2575 West Bellfort
Suite 333
Houston, TX 77054
United States
713-300-5160
http://www.moleculin.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees4

Key Executives

NameTitlePayExercisedYear Born
Mr. Walter V. KlempChairman, CEO, Pres & Founder175kN/A1960
Mr. Jonathan P. Foster CPAChief Financial Officer and Exec. VP104.92kN/A1964
Dr. Donald H. Picker Ph.D.Chief Scientific Officer131.25kN/A1946
Ms. Jacqueline NorthcutConsultant30.05kN/A1962
Mr. Louis Ploth Jr.Independent Advisor118.49kN/A1954
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Moleculin Biotech, Inc., a preclinical-stage pharmaceutical company, focuses on the development of anti-cancer drug candidates. Its lead drug candidate is liposomal Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia. The company also develops other drugs, including WP1066 Portfolio that focuses on the modulation of regulatory transcription factors involved in the progression of cancer; and WP1122 Portfolio, a suite of molecules targeting the metabolic processes involved in cancer and glioblastoma. Moleculin Biotech, Inc. has an agreement with Mayo Clinic to enable additional research on its WP1066 molecule for the possible treatment of a rare form of pediatric brain tumor. The company also has a strategic collaboration with the University of Bergen to develop immune stimulation drug, as well as to expand research on inhibition of brain metastasis by Moleculin's pre-clinical drug WP1066. In addition, it has a collaboration agreement with Emory University to enable expanded cancer research on WP1066 molecule for the treatment of medulloblastoma, a pediatric malignant primary brain tumor. Moleculin Biotech, Inc. was founded in 2015 and is headquartered in Houston, Texas.

Corporate Governance

Moleculin Biotech, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.